Cargando…

Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?

During the ongoing COVID-19 pandemic, serology has suffered several manufacturing and budget bottlenecks. Kode technology exposes exogenous antigens on the surface of cells; in the case of red blood cells, modified cells are called kodecytes, making antibody–antigen reactions detectable by the old-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Franchini, Massimo, Maggi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953758/ https://www.ncbi.nlm.nih.gov/pubmed/35335038 http://dx.doi.org/10.3390/vaccines10030406

Ejemplares similares

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

THE SPECIFICITY OF THE PASSIVE HEMAGGLUTINATION METHODS USED IN SEROLOGY OF TUBERCULOSIS
por: Takahashi, Yoshio, et al.
Publicado: (1961)

Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
por: Ghosh, Joydeep, et al.
Publicado: (2022)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

Serological relation between calf diarrhea coronavirus and hemagglutinating encephalomyelitis virus
por: Sato, K., et al.
Publicado: (1980)

Pharmacogenomic Testing and Antithrombotic Therapy: Ready for Prime Time?
por: Holmes, David R.
Publicado: (2013)

Is sperm DNA fragmentation testing ready for prime time?
por: Jarvi, Keith A.
Publicado: (2017)

Sperm DNA fragmentation testing: ready for prime time?
por: Oehninger, Sergio
Publicado: (2017)

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?
por: Khan, Tahsin M., et al.
Publicado: (2020)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

REBOA: is it ready for prime time?
por: Doucet, Jay, et al.
Publicado: (2017)

The low-dose ACTH test in the ICU: Not ready for prime time
por: Yaegashi, Makito, et al.
Publicado: (2006)

Antibody testing for coronavirus disease 2019: not ready for prime time
por: Duong, Yen T, et al.
Publicado: (2020)

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID19 immune plasma donation after vaccination: pros and cons.
por: Focosi, Daniele, et al.
Publicado: (2021)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

What a Transfusion Physician Should Know about Monkeypox Virus: Barriers to and Risks for Transmission, and Possible Mitigation Strategies
por: Focosi, Daniele, et al.
Publicado: (2022)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
por: Focosi, Daniele, et al.
Publicado: (2022)

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules
por: Focosi, Daniele, et al.
Publicado: (2023)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
por: Jeepalyam, Sravan, et al.
Publicado: (2023)

Is pocket ultrasound ready for prime time?
por: Galen, Benjamin T
Publicado: (2012)

Radiotherapy for HCC: Ready for prime time?
por: Bang, Andrew, et al.
Publicado: (2019)

Commentary: Almost ready for prime time
por: Wei, Lawrence M.
Publicado: (2020)

CGM in the Hospital: Is It Ready for Prime Time?
por: Buschur, Elizabeth O., et al.
Publicado: (2022)

Hemagglutination Induced by Viruses
por: Briody, Bernard A.
Publicado: (1946)

Sperm DNA fragmentation testing: a standard semen test or not ready for prime time?
por: Honig, Stanton C.
Publicado: (2017)

Challenges of Endocrine Function Testing in Resource Poor Settings
por: Charles-Davies, Mabel A.
Publicado: (2010)

COVID-19 testing before every endoscopy: Is India ready for prime time?
por: Sundaram, Sridhar
Publicado: (2020)

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?
por: Sheel, Ankur, et al.
Publicado: (2022)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Glucocorticoid therapy for trauma - ready for prime time?
por: Aleti, Venkata S, et al.
Publicado: (2012)

CT colonography screening: ready for prime time?
por: Heiken, Jay P.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_032prnap1bvl8jll4hem5hm2sm